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Abstract: 
Background: While ventricular assist device (VAD) use in pediatric patients has previously been associated with anti-human 
leukocyte antigen (HLA) antibody production, the clinical significance of these antibodies is unclear. We investigated the clinical 
impact of anti-HLA antibodies associated with VAD use in a large cohort of pediatric heart transplant (HTx) recipients.  
Methods: From 2004-2011, pediatric cardiomyopathy patients post-HTx (N=1,288) with pre-HTx panel reactive antibody (PRA) levels 
were identified from the United Network for Organ Sharing database.  PRA levels were compared between VAD patients and those 
with no history of mechanical circulatory support (MCS).  Incidence of rejection and overall survival were compared between VAD 
and non-MCS groups after stratification by PRA and age.  
Results: VAD recipients were more likely to produce anti-HLA antibodies than non-MCS patients (25.5% vs. 10.5% had PRA>10%, 
p<0.0001).  Sensitized VAD patients (PRA>10%) had a higher incidence of rejection within 15 months of HTx compared to sensitized 
non-MCS patients (57.1% vs. 35.9%, p=0.02).  There was no intergroup difference in 15-month mortality.  Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
Conclusion:
Keywords: Pediatric heart transplant, anti-HLA antibodies, PRA, ventricular assist device, rejection 
  Among pediatric cardiomyopathy patients supported with a VAD, the presence of anti-HLA antibodies prior to HTx is 
associated with an increased risk of rejection. The mechanism of the association between VAD-associated antibodies and early 
rejection is unclear and warrants further investigation.  
 
Introduction:  
Over the past decade, the use of ventricular assist devices (VADs) to support pediatric patients awaiting heart transplantation 
has increased dramatically (1).  Survival outcomes among pediatric patients supported by VADs have generally been quite good, 
with waitlist and post-transplant outcomes equivalent to or better than the general pediatric heart transplant (HTx) population (2-5).  
One concern associated with the increased use of VADs is the potential for increased sensitization, or anti-HLA antibody production, 
among HTx candidates. There is evidence from both adult and pediatric populations that VAD use is associated with increased 
production of anti-HLA antibodies (6-8).   
The pathogenicity of the anti-HLA antibodies produced in association with VAD support is unclear, however.  In the adult 
population, most studies have found no increased rejection in VAD sensitized patients (9-12), however a few studies show an 
increased risk of rejection in patients with VAD associated antibodies (13, 14). Large studies looking specifically at the effect of anti-
HLA antibodies formed in association with VAD support on post-HTx outcomes in children are lacking. 
The purpose of this study was to investigate the clinical impact of anti-HLA antibodies associated with VAD use in a large 
cohort of pediatric cardiomyopathy patients undergoing HTx.  We hypothesized that anti-HLA antibodies associated with the use of 
VAD support were less likely to be associated with rejection compared to non-MCS associated antibodies, as the preponderance of 
adult literature has shown.  In order to maximize the likelihood that antibodies measured prior to HTx were associated with VAD 
support and not due to other exposures, we looked exclusively at patients with a diagnosis of cardiomyopathy, who had no prior 
history of cardiac surgery and were less likely to be previously sensitized than patients with congenital heart disease.  
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A retrospective cohort study was performed using the United Network for Organ Sharing (UNOS) database.  Pediatric HTx 
recipients with a primary diagnosis of cardiomyopathy (restrictive, hypertrophic, dilated, noncompaction or combined) were identified 
in the database from 2004 to 2011.  Patients with a history of congenital heart disease were excluded, as were repeat transplants, 
patients undergoing multi-organ transplantation, or patients who were identified as being on ECMO prior to transplant (in order to try 
to limit sensitization due to other factors). The following patient and clinical characteristics were collected: VAD support prior to 
transplant, type of VAD support (BIVAD vs. LVAD), age, sex, race, primary diagnosis, most recent PRA prior to transplant (if both 
Class I and Class II PRA available, the highest of the two was used), and results of crossmatch.  Due to the high frequency of 
missing data (68%), history of previous transfusions at the time of listing was not included.  Patients were divided into two groups: 
those who received VAD support prior to transplant vs. those with no history of mechanical circulatory support (MCS; VAD or 
ECMO).  Patients within each group were stratified as PRA 0, PRA 1 to 10%, PRA > 10%, and PRA > 50%.   
The primary endpoints were rejection prior to discharge (“hospital rejection”) and within 15 months post-HTx; secondary 
outcomes were mortality due to rejection at 15 months post-transplant and overall survival at 15 months post-transplant.  Rejection 
was defined as a drug treated episode of acute rejection prior to discharge or hospitalization or treatment for rejection within 15 
months of heart transplant.  Biopsy was not a criterion for the diagnosis of rejection in this study; rejection could be diagnosed by 
biopsy, clinically or by echocardiogram. It was therefore a composite outcome that included both cellular, antibody mediated and 
mixed rejection.  Primary graft failure was excluded from the definition of rejection.  Mortality was defined as death or 
retransplantation.  All causes of death were included in the analysis.  Incidence of post-HTx rejection and overall survival were 
compared between VAD and non-MCS groups after stratification by PRA and age.  
Statistical analysis: 
Data were reported as N (%) for categorical variables and median (interquartile range) for continuous variables.  Patient 
characteristics and incidences of sensitization and rejection (in overall groups and after stratification by PRA levels) were compared 
between the VAD and non-MCS groups using Chi-square test or Fisher’s exact test. To examine the effect of increasing PRA on 
rejection within the VAD support group, Chi-square test for trend was used. Mortality due to rejection and overall survival at 15 
months of post-HTx were calculated using Kaplan-Meier estimates and compared between the VAD and non-MCS groups using log-
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rank test. All analyses were performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC). A p-value of <0.05 was considered 
statistically significant.   
Results: 
Patient characteristics 
Patient characteristics are presented in Table 1.  The entire patient cohort included a total of 1,288 patients of whom 51.5% 
were male, 46.7% were Caucasian and 27% were less than 2 years old.  Dilated cardiomyopathy (84.2%) was the most common 
diagnosis, and 21.4% of the patients were supported by a VAD prior to HTx.  The VAD group was slightly older, with a higher 
percentage of non-Caucasians and patients with a diagnosis of dilated cardiomyopathy in comparison to the non-MCS group.  
 
 
Anti-HLA antibodies 
PRA data was available for 83.5% of the patients.  The incidence of anti-HLA antibody production prior to HTx was higher in 
patients 2-18 years old than in those 0-1 year old (30.8% vs. 21.7%, p=0.003).  Anti-HLA antibody production did not appear to be 
influenced by race.  Overall, 11.5% of patients had PRA (class I or class II) >10% prior to HTx (table 2A).  In this cohort overall, the 
incidence of a high degree of sensitization (PRA >50%) was uncommon, with only 44 patients (3.1%) with PRA >50%.  VAD 
recipients were more likely to have PRA >10 % than patients without a history of mechanical support 
Crossmatch results 
(25.5% vs. 10.5%, p<0.0001; 
table 2B).   
Crossmatch results were available for 81.2% of patients.  There was no difference in the incidence of positive crossmatch 
between VAD and non-MCS patients.  Among those with a PRA >0%, 15.8% of patients with no mechanical support had a positive 
crossmatch compared to 23.2% of VAD patients (p=0.12). In the PRA >10% group, 24.4% of those without MCS had a positive 
crossmatch compared to 31.6% of those supported by a VAD (p=0.35).     
Rejection and survival Au
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The overall incidences of rejection prior to hospital discharge and at 15 months post-transplant were 14.8% and 31.4% 
respectively (table 3).  VAD support pre-HTx was associated with increased post-HTx rejection, but only among those patients who 
had developed anti-HLA antibodies (figures 1a and 1b).  Among patients without anti-HLA antibodies, there was no difference in 
rejection either by hospital discharge or at 15 months post-HTx between VAD and non-MCS patients (9.2% vs. 13.2% prior to 
discharge and 33.3% vs. 34.8% at 15 months, p=0.21 and p=0.78, respectively).  In comparing VAD and non-MCS sensitized 
patients (PRA >10%) there was no difference in the incidence of rejection prior to discharge (25% in the VAD group vs. 18.2% in the 
non-MCS group, p= 0.32), however at 15 months post-HTx, a history of VAD support pre-HTx was associated with increased 
rejection (57.1% vs. 35.9%, p=0.02).  Only 44 patients were highly sensitized (PRA > 50%), and while the rates of rejection prior to 
hospital discharge (26.3% vs 5.6%) and within 15 months of HTx  (61.5% vs 33.3%) were higher among the VAD group than the 
non-MCS group, these differences were not statistically significant (p=0.18 and p=0.16, respectively).  Primary graft failure was rare, 
and there was no difference in the incidence of primary graft failure between the sensitized VAD and sensitized non-MCS group.  
To more carefully examine the effect of higher levels of PRA within the VAD and non-MCS groups, we looked at PRA levels 
of 0, 1 to 10%, 11-50%, and >50%.  Among VAD supported patients, higher PRA was associated with an increased incidence of 
rejection prior to hospital discharge and within 15 months of transplant (figure 2a).  Incidence of rejection prior to hospital discharge 
increased from 9.2% for those with PRA 0, to 26.3% for PRA >50% (p= 0.004).  Incidence of rejection at 15 months increased from 
33.3% for those with PRA of 0, to 61.5% for a PRA >50% (p= 0.02).  Increasing PRA was not associated with increased rejection 
among patients who had not received MCS prior to transplant (figure 2b).  Within the non-MCS group, the incidence of rejection at 15 
months was relatively static at approximately 35% regardless of PRA level.  
Despite increased rejection among sensitized VAD patients, there was no difference in rejection-related mortality or overall 
survival between VAD and non-MCS patients regardless of PRA (table 4).  Overall survival was 92.8% for VAD and 93.3% for non-
MCS patients at 15 months (p=0.64).  Increasing PRA did not affect overall survival for either group.  Among VAD patients, 15 month 
survival was 90.9% for those with a PRA of 0, 94.9% for those with a PRA 1 to 10%, and 92.6% for those with a PRA >10% (p=0.68).  
Similarly among non-MCS patients, 15 month survival was 93.3%, 93.7% and 91.1% for those with a PRA of 0, 1 to 10% and >10%, 
respectively (p=0.39).      
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DISCUSSION:  
This analysis found that among pediatric cardiomyopathy patients, a history of VAD support both increases the likelihood of 
anti-HLA antibody production and increases the risk of early rejection in those patients who do become sensitized.  Among VAD 
patients, the risk of early rejection increased as PRA became more elevated, from 33.3% in patients with a PRA of 0 to 61.5% in 
patients with a PRA >50%.  In contrast, the incidence of early rejection remained steady at approximately 35% regardless of PRA 
among patients who did not receive MCS prior to transplant.  VAD support by itself was not associated with increased rejection, as 
there was no difference in rejection between VAD and non-MCS patients with a PRA of 0.  The increased risk of rejection in the 
sensitized VAD group did not appear to be influenced by a higher incidence of a positive crossmatch, as there was no difference in 
the incidence of a positive crossmatch between the sensitized VAD and non-VAD patients.  Mortality did not appear to be impacted 
by PRA in either group.   
Anti-HLA antibodies have been associated with inferior post-HTx outcomes in adults (15, 16) and children, with increased 
graft failure (17) and increased mortality (18).  The reasons for these inferior outcomes are unclear; possibilities include increased 
rejection, primary graft dysfunction, and early coronary allograft vasculopathy (17).  In pediatric patients, some studies have shown 
an increased risk of rejection with elevated PRA (19, 20), while others have not (18, 21).  The use of VADs is associated with an 
increased incidence of sensitization (7, 8, 22), however it is unclear if antibodies associated with VAD exposure have the same 
clinical significance as antibodies formed as a result of other sensitizing events, such as exposure to human allograft material or 
blood products (23, 24).   
In this study, we aimed to assess the clinical impact of anti-HLA antibodies produced in the setting of VAD support.  In order 
to decrease the likelihood that antibodies measured in VAD patients were present prior to VAD exposure, we chose to limit the study 
population to patients diagnosed with cardiomyopathy, a population with a lower likelihood of prior sensitizing events than patients 
with congenital heart disease.  The 25.5% incidence of sensitization seen in the VAD supported patients in this study is lower than 
prior reports of 35-69% sensitization in the general pediatric VAD population (7, 8), likely reflecting the exclusion of many pre-
sensitized patients with congenital heart disease and eliminating confounding etiologies of PRA sensitization that may have different 
pathogenicity.  Interestingly, the incidence of sensitization found in this study was similar to the 22% incidence of new sensitization 
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after VAD placement in an adult cohort supported by continuous flow VADs (13).  Furthermore, only 10.5% of the non-VAD group 
was sensitized, suggesting that the majority of anti-HLA antibodies in the VAD group were likely associated with VAD exposure.    
The data regarding pathogenicity of anti-HLA antibodies produced by pediatric VAD patients are limited.  One small single  
center study did appear to show a trend towards increased risk of rejection among sensitized pediatric VAD patients compared to 
non-sensitized VAD patients, though this difference did not reach statistical significance, possibly due to limitations in sample size 
(7).  The data regarding VAD associated antibodies in adults are conflicting, with some studies showing an increased the risk for 
allograft rejection (13, 14) and others finding no increased risk of rejection in those with VAD associated antibodies (9-11).  There are 
several potential explanations for these disparate results, including variability in the method of evaluating anti-HLA antibodies among 
different centers, and potential differences in antibody reduction strategies.  Information regarding PRA technique and approach to 
densensitization is not available in the UNOS database and could not be controlled for in our study.  Interestingly, in the largest adult 
study showing no difference in rejection between VAD sensitized and non-VAD sensitized patients, immunotherapy information was 
similarly lacking (11).  However, in a smaller, single center adult study, sensitized untreated VAD patients did have an increased risk 
of rejection compared to sensitized but treated, as well as non-sensitized, VAD patients (14).  Data on antibody reduction strategies 
utilized in our patient population would shed further light on potential management strategies that might lead to differences in post-
transplant outcome.   
The mechanism by which sensitized VAD patients appear to have increased early rejection compared to sensitized non-MCS 
patients is not clear, and attempts to generate likely hypotheses are limited by the lack of data on antibody specificity available in the 
UNOS database.  While one interpretation of our data could be that VAD-associated antibodies have increased pathogenicity, the 
lack of a difference in positive crossmatch frequency between groups suggests that the antibodies present may not necessarily have 
been donor specific, and may not have been directly responsible for the early rejection seen.  An alternative hypothesis is that the 
anti-HLA antibodies measured by PRA may not be directly involved in rejection, but instead could be a marker of a generalized 
activation of the immune system caused by VAD exposure in some patients.  LVAD implantation has been shown to initiate immune 
and inflammatory responses, at least in part due to the formation of pseudointima (composed of T cells, macrophages and 
monocytes) on the surface of these devices (25, 26).  T-cell dysregulation, B-cell hyperreactivity and abnormal antibody production 
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have been reported in LVAD recipients (27).  In this study, the finding of increased rejection prior to discharge among VAD patients 
with very low level antibody production (PRA 1 to 10%) is consistent with this antibody production being a marker for an inflammatory 
state.  If the HLA antibodies detected are really a marker for a generalized activation of the immune system, then it may be that the 
patients were at increased risk for cellular as well as antibody mediated rejection. This hypothesis is supported by a recent article by 
Ko et al, which showed that sensitized VAD patients had an increased risk of both cellular and antibody mediated rejection (28).  An 
additional hypothesis to explain our findings could be that different antibody reduction strategies or immunosuppression were used 
for VAD and non-MCS sensitized patients.  If that were the case, then the increased risk of rejection seen among the VAD patients in 
this study may be modifiable.  
Despite the increased risk of rejection in VAD sensitized patients, this group had a similar survival at 15 months when 
compared to other sensitized patients. There are no pediatric studies regarding survival in sensitized VAD patients compared with 
sensitized non-VAD patients, and data regarding post-transplant survival in the overall population of sensitized pediatric patients are 
conflicting (17, 18).  Adult studies which specifically investigated VAD associated antibodies support our findings, with no difference 
in overall survival seen in VAD versus non-VAD patients with PRA >10 (9, 11, 12, 29), even when increased rejection was found 
(28). 
Limitations: 
This study had several limitations.  The overall rate of sensitization in this cohort was low (11.5%) which reduces the power of 
the study and potentially limits the conclusions that can be drawn.  As this was a retrospective study using a large database (UNOS), 
we were limited to the information collected in the database.  Specifically, there was no information regarding pre- or post-transplant 
immune modulation or antibody reduction strategies. Transfusion history was lacking in a large percentage of patients so this could 
not be analyzed as a variable influencing the incidence of sensitization between the groups.  We were unable to determine what 
percent of rejection episodes were proven by biopsy, as that variable was only part of the UNOS database until 2007.  Therefore, we 
do not know the incidence of antibody mediated rejection or cellular rejection, and it is possible that true number of rejection episodes 
may have been either more or less than captured by this study.  Information regarding the way in which PRA was calculated was not 
available in the database, and we did not have access to the antigen-specific data available from newer solid phase single antigen 
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bead techniques of PRA calculation.  The lack of data regarding antibody specificity, in combination with the lack of information about 
whether the reported rejection was antibody mediated or cellular, complicates the attempt to hypothesize on likely mechanisms for 
the increased rejection in sensitized VAD patients.  Antibody levels likely vary at different points in time after VAD implantation (30), 
and the dataset only captures the most recent PRA.  Furthermore, information regarding timing of VAD implantation and most recent 
PRA level was not available; it is possible that the PRA reported could have been drawn prior to VAD implantation.  We are also 
unable to differentiate between antibodies formed before and after VAD placement, although we did make an effort to minimize the 
number of pre-VAD antibodies by restricting the population to cardiomyopathy patients.  Antibody class (I or II) was not analyzed due 
to lack of adequate data.  Finally, we did not have enough data regarding VAD type to include this in our analysis.  
Conclusion: 
In the pediatric cardiomyopathy population, the combination of VAD support and anti-HLA antibody production appears to be 
associated with an increased incidence of early rejection.  Sensitized VAD patients have increased rates of early rejection compared 
to both non-sensitized VAD patients and comparably sensitized non-VAD patients.  The mechanism of increased rejection in this 
population, and the potential for modifying the risk of rejection through peri- and post-transplant antibody reduction therapy, are 
unknown and warrant further investigation.   
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Figure legends:  
Figure 1a and 1b: 
*
Abbreviations: VAD, ventricular assist device; MCS, mechanical circulatory support; PRA, panel reactive antibody 
Including deaths and retransplants due to rejection 
P-value from Chi-square test or Fisher’s exact test, as appropriate 
 
Figure 2a and 2b: 
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*Including deaths and retransplants due to rejection 
Abbreviations: HTx, heart transplant; VAD, ventricular assist device; PRA, panel reactive antibody 
P-value from Chi-square test for trend 
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Table 1.   Comparison of patient and clinical characteristics 
 
                                                                                      Overall                             VAD                       No MCS                       
                                                                                    (n= 1,288)                        (n=275)                  (n= 1,010)               p-value
§
 
Median age at transplant, years                         10 (1-14)                          
Age at transplant, years                                
                                 0-1                                         350 (27.2)                       60 (21.8)                 290 (28.7)                     0.02         
                                 2-18                                       938 (72.8)                     215 (78.2)                 720 (71.3)           
Male sex                                                                663 (51.5)                     155 (56.4)                 507 (50.2)                    0.07          
Race 
                Caucasian                                               601 (46.7)                    117 (42.5)                  482 (47.7)                                    
                African American                                  343 (26.6)                      87 (31.6)                  256 (25.3)             
                Hispanic                                                  227 (17.6)                      37 (13.5)                  189 (18.7)                   0.01          
                Asian                                                          74 (5.7)                        25 (9.1)                      49 (4.9)                
                Other                                                          43 (3.3)                          9 (3.3)                      34 (3.4)   
Primary diagnosis 
                 Dilated cardiomyopathy                    1085 (84.2)                  268 (97.5)                   814 (80.6)                                    
                 Restrictive cardiomyopathy                146 (11.3)                       4 (1.5)                     142 (14.1)               <0.001 
                 Hypertrophic cardiomyopathy              57 (4.4)                         3 (1.1)                       54 (5.3) 
Data are presented as N (%); median age is presented as age (interquartile range) 
Abbreviations: VAD, ventricular assist device; MCS, mechanical circulatory support 
§
P-value from Chi-square test; comparison is between VAD vs. no MCS group 
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Table 2. Incidence of sensitization  
A. Overall sensitization 
Most recent PRA prior to transplant, %
1
       
                  0                                                                                                                                   772 (59.9) 
               1-10                                                                                                                              156 (12.1) 
               >10                                                                                                                               148 (11.5) 
               >50                                                                                                                                  44  (3.1) 
               Unknown                                                                                                                     212 (16.5) 
 
B. Sensitization by type of support pre-transplant 
                                                                                                                              Incidence                             
                                                                                                         PRA >10%                    PRA  >50%      p-value
§
 
Type of support pre-transplant 
                   No mechanical support                                           88 (10.5)                      18 (2.1)          <.0001 
                   VAD only (LVAD or BiVAD)                                      60 (25.5)                      19 (8.1)          <.000 
Abbreviations: PRA, panel reactive antibody; VAD, ventricular assist device; LVAD, left ventricular assist device; BiVAD, 
biventricular assist device 
Data are presented as N (%) for categorical variables and median (interquartile range) for continuous  variables 
1
If both class I and class II PRA were available, the highest PRA was used 
Data are presented as N (%) 
§
 P-value from Chi-square test 
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Table 3. Outcome measures  
Acute rejection episode(s) prior to hospital discharge                                                     191 (14.8) 
Rejection
1
 within 15 months of HTx                                                                                     404 (31.4) 
Death within 15 months of HTx due to rejection                                                                 27 (2.1) 
Re-HTx within 15 months of HTx due to rejection                                                                 2 (0.2) 
Time from HTx to discharge, days                                                                                          15 (11-23) 
Abbreviations: HTx, heart transplant 
Data are presented as N (%) for categorical variables and median (interquartile range) for continuous  variables 
1
Including deaths and retransplants due to rejection 
 
 
 
 
 
 
 
 
 
Table 4. Mortality due to rejection and overall survival at 15 months post-transplant 
                                                                                                       Mortality due to                      Overall survival                 
                                                                  # of patients                    rejection                         
 PRA levels          Type of support           available                 Rate          p-value
§
                    Rate        p-value
§
 
  
PRA= 0                     No MCS                      640                          2.4               0.08                         93.3          0.27 
(n= 772)                      VAD                         130                           5.1                                               90.9 
 
PRA 1-10%             No MCS                      110                           2.2               0.40                         93.7           0.87 
(n= 304)                      VAD                          45                             0                                                  94.9 
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PRA >10%                No MCS                      88                            3.3               0.68                          91.1          0.77 
(n= 148)                      VAD                          60                            4.2                                                 92.6 
PRA >50%                
(n= 37)                      No MCS__                 18____________ 15.4____    0.58                         _84.6__    0.63 
                                      VAD                         19                            7.7                                                 82.0 
Abbreviations: PRA, panel reactive antibody; MCS, mechanical circulatory support; VAD, ventricular assist device 
Rates were derived from the Kaplan-Meier method 
§
P-value from log-rank test 
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Figure 1a.       
    .  
Figure 1b. 
 
*Including deaths and retransplants due to rejection 
Abbreviations: VAD, ventricular assist device; MCS mechanical circulatory support; PRA, panel 
reactive antibody 
P-value from Chi-square test or Fisher’s exact test, as appropriate 
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  Figure 2a.  
 
Figure 2b.  
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*Including deaths and retransplants due to rejection 
Abbreviations: HTx, heart transplant; VAD, ventricular assist device; PRA, panel reactive antibody 
P-value from Chi-square test for trend 
 
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
